CAR-CLL1 therapy also shows great therapeutic potential in R/R AML, and CAR-CLL1 bridging allo-HSCT is a treatment option for R/R AML (8).This case highlights a novel salvage strategy for CAR-T-refractory R/R AML using UCB, PBSCT, and DLI. Here, CLEC12A is linked to acute myeloid leukemia.